Oncology
Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, today announced RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium). RenovoTAMP is a unique therapy platform…
Read More
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissue No dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma (rHGG) Median overall survival was 11.6 months after a single injection of CAN-3110 in patients with rHGG; one patient achieved a complete response lasting more than one year…
Read More
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapy Patient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients with visceral angiosarcoma 67% of patient responses have…
Read More
Methylation Approach Had One of the Highest Cancer Signal Detection Sensitivities and Best Predicted Cancer Signal Origin of the Evaluated Technologies Approach Informed Development of Galleri® Multi-Cancer Early Detection Blood Test Analysis is Part of Extensive and Systematic Comparison of Cancer Specific Cell-Free DNA Features for Multi-Cancer Early Detection Excerpt from the Press Release: MENLO…
Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost memory T cell responses to disease, debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12,…
Read More
TPST-1120 Late-breaking Poster Presentation at SITC Annual Meeting Second Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology…
Read More
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 program Excerpt from the Press Release: SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with…
Read More
The multicenter Phase 1 study is currently enrolling and evaluating IO-202 as monotherapy and in combination with an anti-PD-1 for the treatment of solid tumors Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced that it will present…
Read More
Data show trend in decreasing Tregs, presenting unique profile among current IL-2 therapeutics Adding Phase 1/2 clinical trial sites in the U.S. following recent IND application clearance Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today presented early…
Read More
Excerpt from the Press Release: A team of researchers at the University of Washington School of Medicine (UWSM) has been working on a breast cancer vaccine for over the last 20 years. In their recently published study, they finally revealed the results of the phase one human trials of their breast cancer vaccine. A WHO…
Read More